SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
OXiGENE Announces Phase 2 Ovarian Cancer Trial of ZYBRESTAT(R) Plus Bevacizumab Achieves Important Interim Safety Objective